- Home
- PAVS vs MAIA Comparison
PAVS vs MAIA Comparison
Compare PAVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- MAIA
- Stock Information
- Founded
- PAVS 2004
- MAIA 2018
- Country
- PAVS United States
- MAIA United States
- Employees
- PAVS N/A
- MAIA N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PAVS Health Care
- MAIA Health Care
- Exchange
- PAVS Nasdaq
- MAIA Nasdaq
- Market Cap
- PAVS 49.1M
- MAIA 56.3M
- IPO Year
- PAVS 2019
- MAIA 2022
- Fundamental
- Price
- PAVS $0.78
- MAIA $1.70
- Analyst Decision
- PAVS
- MAIA
- Analyst Count
- PAVS 0
- MAIA 0
- Target Price
- PAVS N/A
- MAIA N/A
- AVG Volume (30 Days)
- PAVS 146.2K
- MAIA 464.6K
- Earning Date
- PAVS 08-04-2025
- MAIA 11-11-2025
- Dividend Yield
- PAVS N/A
- MAIA N/A
- EPS Growth
- PAVS N/A
- MAIA N/A
- EPS
- PAVS N/A
- MAIA N/A
- Revenue
- PAVS $71,542.00
- MAIA N/A
- Revenue This Year
- PAVS N/A
- MAIA N/A
- Revenue Next Year
- PAVS N/A
- MAIA N/A
- P/E Ratio
- PAVS N/A
- MAIA N/A
- Revenue Growth
- PAVS N/A
- MAIA N/A
- 52 Week Low
- PAVS $0.32
- MAIA $1.40
- 52 Week High
- PAVS $1.50
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- PAVS 48.90
- MAIA 58.76
- Support Level
- PAVS $0.76
- MAIA $1.54
- Resistance Level
- PAVS $0.90
- MAIA $1.78
- Average True Range (ATR)
- PAVS 0.11
- MAIA 0.09
- MACD
- PAVS 0.01
- MAIA 0.02
- Stochastic Oscillator
- PAVS 27.27
- MAIA 75.00
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.